Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study.

被引：0
|
作者：
Fernandez Montes, Ana
Ros, Javier
Grana, Begona
Garcia-Alfonso, Pilar
Brozos, Elena
Melian, Marcos
Jimenez-Gordo, Ana M.
Martinez de Castro, Eva
Busquier, Isabel
Gallego, Javier
Gravalos, Cristina
Covela, Marta
Ruiz-Casado, Ana
Gonzalez Flores, Encarnacion
Safont, Mariajose
Maria Cano, Juana
Alonso Lopez, Carmen
Gomez-Reina, Maria Jose
Donnay, Olga
Aranda, Enrique
机构：
[1] Complexo Hosp Univ Ourense CHUO, Dept Med Oncol, Orense, Spain
[2] Vall dHebron Univ Hosp CHUO, Dept Med Oncol, Barcelona, Spain
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] A Coruna Univ Hosp, Inst Invest Biomed INIBIC, La Coruna, Spain
[5] Hosp Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain
[6] CHUS, Santiago De Compostela, Spain
[7] Inst Valenciano Oncol, Valencia, Spain
[8] Hosp Univ Infanta Sofia, Dept Med Oncol, San Sebastian Los Reyes, Spain
[9] Univ Hosp Marques de Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain
[10] Hosp Prov Castellon, Valencia, Spain
[11] Hosp Gen Univ Elche, Alicante, Spain
[12] Hosp Univ 12 Octubre, Madrid, Spain
[13] Hosp Univ Lucas Augusti HULA, Lugo, Spain
[14] Hosp Univ Puerta de Hierro, Dept Med Oncol, Madrid, Spain
[15] Hosp Virgen de las Nieves, Granada, Spain
[16] Hosp Gen Valencia, Valencia, Spain
[17] Hosp Gen Univ Ciudad Real, Ciudad Real, Spain
[18] Complejo Hosp Univ Albacete, Albacete, Spain
[19] Hosp Univ Nuestra Senora de Valme, Seville, Spain
[20] Hosp Univ Princesa, Madrid, Spain
[21] Hosp Univ Reina Sofia, Cordoba, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
126
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [41] Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer following progression on prior BRAF plus EGFR targeted therapies.
    Pan, Kelsey
    Baig, Yunyu
    Willis, Jason
    Dasari, Arvind
    Bent, Alisha Heather
    Higbie, Victoria
    Huey, Ryan W.
    Kee, Bryan K.
    Lee, Michael Sangmin
    Parseghian, Christine
    Morelli, Maria Pia
    Shen, John Paul Y. C.
    Kopetz, Scott
    Morris II, Van K.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 182 - 182
  • [42] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Shuosha Li
    Huabin Hu
    Dong Ding
    Youwen Zhu
    Jin Huang
    Advances in Therapy, 2021, 38 : 1650 - 1659
  • [43] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Li, Shuosha
    Hu, Huabin
    Ding, Dong
    Zhu, Youwen
    Huang, Jin
    ADVANCES IN THERAPY, 2021, 38 (03) : 1650 - 1659
  • [44] Efficacy of vemurafenib, a selective BRAFV600E inhibitor, in combination with a MEK inhibitor in BRAFV600E colorectal cancer models.
    Higgins, Brian
    Kolinsky, Kenneth Daniel
    Yang, Hong
    Kim, Min Jung
    Li, Jia Kui
    Go, Zenaida
    Packman, Kathryn
    Bollag, Gideon
    Su, Fei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [45] Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?
    de la Fouchardiere, Christelle
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (21)
  • [46] BRAFV600E mutation promoted the growth and chemoresistance of colorectal cancer
    Ma, Zenghui
    Qi, Zhenguang
    Gu, Chaofeng
    Yang, Zhou
    Ding, Yue
    Zhou, Yichan
    Wang, Wei
    Zou, Qi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (04): : 1486 - 1497
  • [47] Insight on BRAFV600E mutated colorectal cancer immune microenvironment
    Abushukair, Hassan Mohammed
    Zaitoun, Sara Mu'amar
    Saeed, Anwaar
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (06) : 1213 - 1215
  • [48] Insight on BRAFV600E mutated colorectal cancer immune microenvironment
    Hassan Mohammed Abushukair
    Sara Mu'amar Zaitoun
    Anwaar Saeed
    World Journal of Gastrointestinal Oncology, 2022, 14 (06) : 1213 - 1215
  • [49] SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
    Morris, Van K.
    Guthrie, Katherine A.
    Kopetz, Scott
    Breakstone, Rimini
    Karasic, Thomas Benjamin
    Hu, Zishuo Ian
    Colby, Sarah
    Fakih, Marwan
    Gholami, Sepideh
    Gold, Philip Jordan
    Philip, Philip A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS234 - TPS234
  • [50] BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)
    Kopetz, Scott
    Grothey, Axel
    Yaeger, Rona
    Ciardiello, Fortunato
    Desai, Jayesh
    Kim, Tae Won
    Maughan, Tim
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Edwards, Michelle L.
    Golden, Adele
    Gollerkeri, Ashwin
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345